SLE with Sjogren's syndrome: epratuzumab shows efficacy in EMBODY trials

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with systemic lupus erythematosus (SLE) with associated Sjogren's syndrome (aSjS), the anti-CD22 monoclonoal IgG antibody epratuzumab showed safety and improvements in SLE disease activity, including decreases in B cells compared with patients with SLE without aSjS.

Why this matters

  • Epratuzumab warrants further clinical study in this subpopulation of patients with SLE.

Study design

  • This was a post hoc analysis of the EMBODY clinical trials in which 1584 patients with SLE were randomly assigned to epratuzumab or placebo.
  • 113 patients with SLE with aSjS were compared with 1375 patients with SLE without aSjS.
  • Funding: UCB Pharma.

Key results

  • A higher percentage of epratuzumab patients with aSjS achieved a BICLA (British Isles Lupus Assessment Group [BILAG] Combined Lupus Assessment) response and a lowering from baseline of BILAG total score (P<.05).
  • Patients with vs without aSjS had faster B-cell reduction, as measured by lower mean concentration producing 50% of the maximum B-cell count depletion (9.47 vs 87.1 μg/mL).
  • There was no difference between epratuzumab and placebo in the frequency of adverse events.

Limitations

  • Post hoc analysis.